HK1245154A1 - 抗cd47抗體及其用途 - Google Patents
抗cd47抗體及其用途Info
- Publication number
- HK1245154A1 HK1245154A1 HK18104961.7A HK18104961A HK1245154A1 HK 1245154 A1 HK1245154 A1 HK 1245154A1 HK 18104961 A HK18104961 A HK 18104961A HK 1245154 A1 HK1245154 A1 HK 1245154A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098291P | 2014-12-30 | 2014-12-30 | |
| PCT/US2015/067642 WO2016109415A1 (en) | 2014-12-30 | 2015-12-28 | Anti-cd47 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1245154A1 true HK1245154A1 (zh) | 2018-08-24 |
Family
ID=56284963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18104961.7A HK1245154A1 (zh) | 2014-12-30 | 2018-04-17 | 抗cd47抗體及其用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10870699B2 (zh) |
| EP (1) | EP3240569A4 (zh) |
| JP (2) | JP6850255B2 (zh) |
| KR (1) | KR102489471B1 (zh) |
| CN (1) | CN107530421B (zh) |
| AU (1) | AU2015374301B2 (zh) |
| BR (1) | BR112017014258A2 (zh) |
| CA (1) | CA2972604C (zh) |
| CL (1) | CL2017001736A1 (zh) |
| CO (1) | CO2017007673A2 (zh) |
| EA (1) | EA037654B1 (zh) |
| EC (1) | ECSP17041865A (zh) |
| HK (1) | HK1245154A1 (zh) |
| MX (1) | MX2017008819A (zh) |
| SG (2) | SG10202007176TA (zh) |
| WO (1) | WO2016109415A1 (zh) |
| ZA (1) | ZA201704467B (zh) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202007176TA (en) | 2014-12-30 | 2020-08-28 | Celgene Corp | Anti-cd47 antibodies and uses thereof |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| AU2017292752B2 (en) * | 2016-07-06 | 2023-07-27 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| CA3035681A1 (en) | 2016-09-29 | 2018-04-05 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| CN114773471A (zh) | 2016-10-20 | 2022-07-22 | 天境生物科技(上海)有限公司 | 新的cd47单克隆抗体及其应用 |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| US11352425B2 (en) * | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| PE20191080A1 (es) | 2016-11-18 | 2019-08-20 | Beijing Hanmi Pharmaceutical Co Ltd | Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo |
| US11267885B2 (en) * | 2017-01-26 | 2022-03-08 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
| CN110300603B (zh) * | 2017-02-14 | 2023-04-14 | 亘喜生物科技（上海）有限公司 | Cd47-car-t细胞 |
| AU2018244276A1 (en) * | 2017-03-27 | 2019-10-17 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| BR112020001679A2 (pt) * | 2017-08-02 | 2020-07-21 | Phanes Therapeutics, Inc. | anticorpos anti-cd47 e usos dos mesmos |
| SG11202001425TA (en) * | 2017-08-18 | 2020-03-30 | Ultrahuman Four Ltd | Binding agents |
| EP3541941A4 (en) * | 2017-11-10 | 2019-12-25 | I-Mab Biopharma US Limited | FUSION PROTEINS CONTAINING ANTI-CD47 ANTIBODIES AND CYTOKINES |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| KR20200093639A (ko) * | 2017-12-04 | 2020-08-05 | 북경한미약품 유한공사 | 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조 |
| KR20200116109A (ko) * | 2018-01-24 | 2020-10-08 | 난징 레전드 바이오테크 씨오., 엘티디. | 상당한 적혈구 응집을 야기하지 않는 항-cd47 항체 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| WO2019241732A1 (en) | 2018-06-15 | 2019-12-19 | Accurus Biosciences, Inc. | Blocking antibodies against cd47 and methods of use thereof |
| CN112601544A (zh) * | 2018-07-05 | 2021-04-02 | 三钰生物科技股份有限公司 | 人类抗cd47抗体及其用途 |
| CN110872348B (zh) * | 2018-09-03 | 2021-09-03 | 长春金赛药业有限责任公司 | 人源化抗cd47单克隆抗体及其应用 |
| CN112105386A (zh) * | 2018-10-31 | 2020-12-18 | 天境生物科技(上海)有限公司 | 新的cd47抗体及其使用方法 |
| BR112021017399A2 (pt) | 2019-03-06 | 2021-11-16 | Jiangsu Hengrui Medicine Co | Proteína de fusão bifuncional e uso farmacêutico da mesma |
| TW202104260A (zh) * | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| MA56119A (fr) | 2019-06-07 | 2022-04-13 | Alx Oncology Inc | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
| KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| JP7520972B2 (ja) * | 2019-10-25 | 2024-07-23 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗ｃｄ４７抗体及びその使用 |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| US11920136B2 (en) | 2020-02-28 | 2024-03-05 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| JP2023531678A (ja) | 2020-06-22 | 2023-07-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 加齢筋肉、萎縮性筋肉、または異栄養性筋肉の処置のためのｔｓｐ－１阻害物質 |
| JP2023544254A (ja) * | 2020-09-14 | 2023-10-23 | ストロ バイオファーマ， インコーポレイテッド | 無細胞タンパク質合成系を用いた抗体の大規模産生方法 |
| CN116685348A (zh) | 2020-10-07 | 2023-09-01 | 细胞基因公司 | 淋巴恶性肿瘤病状的双特异性抗体治疗 |
| EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| MX2023007667A (es) * | 2020-12-23 | 2023-10-30 | Guangdong Fapon Biopharma Inc | Anticuerpo dirigido contra cd47 y su aplicacion. |
| EP4276113A1 (en) | 2021-01-08 | 2023-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to cd47 and antigen-binding fragment thereof |
| JP2024510989A (ja) | 2021-03-12 | 2024-03-12 | メンドゥス・ベスローテン・フェンノートシャップ | ワクチン接種方法及びｃｄ４７遮断薬の使用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| MX2024005066A (es) | 2021-10-29 | 2024-05-24 | Gilead Sciences Inc | Compuestos de cd73. |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| IL315083A (en) | 2022-03-17 | 2024-10-01 | Gilead Sciences Inc | The IKAROS family of zinc fingers degrades and uses them |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| AU2023256670A1 (en) | 2022-04-21 | 2024-10-17 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| KR20240003755A (ko) * | 2022-06-29 | 2024-01-09 | 고려대학교 산학협력단 | 인간 FcγRs 결합력이 제거된 당화 Fc 변이체들 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240010714A1 (en) * | 2022-07-10 | 2024-01-11 | Mbrace Therapeutics, Inc. | Cell-free methods of recombinant antibody production |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1233987B1 (en) | 1999-11-29 | 2009-08-19 | Bac Ip B.V. | Immobilized single domain antigen-binding molecules |
| JP2005538706A (ja) | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CN101646457B (zh) | 2007-03-20 | 2013-05-01 | 伊莱利利公司 | 抗硬骨素抗体 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| PL2477648T3 (pl) | 2009-09-15 | 2022-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych |
| JP2014519338A (ja) * | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | 治療薬として使用される可溶性タンパク質 |
| ES2816647T3 (es) * | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| ES2743203T3 (es) | 2012-02-06 | 2020-02-18 | Inhibrx Inc | Anticuerpos CD47 y métodos de uso de los mismos |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| EP2953643B1 (en) * | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| DK2986731T3 (da) * | 2013-04-19 | 2022-08-01 | Sutro Biopharma Inc | Ekspression af biologisk aktive proteiner i et bakteriecellefrit syntesesystem ved hjælp af celleekstrakter med forhøjede niveauer af exogene chaperoner |
| SG10202007176TA (en) | 2014-12-30 | 2020-08-28 | Celgene Corp | Anti-cd47 antibodies and uses thereof |
| CA2998644A1 (en) | 2015-09-18 | 2017-03-23 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
| AU2016326423A1 (en) | 2015-09-21 | 2018-04-26 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
-
2015
- 2015-12-28 SG SG10202007176TA patent/SG10202007176TA/en unknown
- 2015-12-28 SG SG11201705310TA patent/SG11201705310TA/en unknown
- 2015-12-28 CA CA2972604A patent/CA2972604C/en active Active
- 2015-12-28 JP JP2017535814A patent/JP6850255B2/ja active Active
- 2015-12-28 WO PCT/US2015/067642 patent/WO2016109415A1/en active Application Filing
- 2015-12-28 BR BR112017014258A patent/BR112017014258A2/pt active Search and Examination
- 2015-12-28 AU AU2015374301A patent/AU2015374301B2/en active Active
- 2015-12-28 CN CN201580077136.5A patent/CN107530421B/zh active Active
- 2015-12-28 US US15/541,003 patent/US10870699B2/en active Active
- 2015-12-28 EA EA201791485A patent/EA037654B1/ru unknown
- 2015-12-28 MX MX2017008819A patent/MX2017008819A/es unknown
- 2015-12-28 KR KR1020177021330A patent/KR102489471B1/ko active IP Right Grant
- 2015-12-28 EP EP15876093.4A patent/EP3240569A4/en active Pending
-
2017
- 2017-06-29 CL CL2017001736A patent/CL2017001736A1/es unknown
- 2017-06-30 ZA ZA2017/04467A patent/ZA201704467B/en unknown
- 2017-06-30 EC ECIEPI201741865A patent/ECSP17041865A/es unknown
- 2017-07-28 CO CONC2017/0007673A patent/CO2017007673A2/es unknown
-
2018
- 2018-04-17 HK HK18104961.7A patent/HK1245154A1/zh unknown
-
2020
- 2020-10-29 US US16/949,459 patent/US11787860B2/en active Active
- 2020-12-01 JP JP2020199312A patent/JP2021048858A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170100652A (ko) | 2017-09-04 |
| WO2016109415A1 (en) | 2016-07-07 |
| SG11201705310TA (en) | 2017-07-28 |
| ZA201704467B (en) | 2019-09-25 |
| US10870699B2 (en) | 2020-12-22 |
| ECSP17041865A (es) | 2017-08-31 |
| BR112017014258A2 (pt) | 2018-03-06 |
| JP2018506964A (ja) | 2018-03-15 |
| CN107530421A (zh) | 2018-01-02 |
| CA2972604A1 (en) | 2016-07-07 |
| SG10202007176TA (en) | 2020-08-28 |
| JP2021048858A (ja) | 2021-04-01 |
| US11787860B2 (en) | 2023-10-17 |
| US20210054070A1 (en) | 2021-02-25 |
| CL2017001736A1 (es) | 2018-03-16 |
| US20170369572A1 (en) | 2017-12-28 |
| EP3240569A4 (en) | 2018-05-30 |
| EP3240569A1 (en) | 2017-11-08 |
| CN107530421B (zh) | 2021-07-20 |
| AU2015374301B2 (en) | 2021-02-11 |
| CA2972604C (en) | 2023-07-04 |
| JP6850255B2 (ja) | 2021-03-31 |
| CO2017007673A2 (es) | 2018-01-05 |
| EA201791485A1 (ru) | 2018-02-28 |
| MX2017008819A (es) | 2018-03-14 |
| KR102489471B1 (ko) | 2023-01-18 |
| AU2015374301A1 (en) | 2017-07-20 |
| EA037654B1 (ru) | 2021-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245154A1 (zh) | 抗cd47抗體及其用途 | |
| HK1255067A1 (zh) | 抗c10orf54抗體及其用途 | |
| HK1243440A1 (zh) | 抗白細胞介素-33抗體及其用途 | |
| HK1254861A1 (zh) | 抗lag3抗體及其用途 | |
| HK1249911A1 (zh) | 抗muc16抗體及其應用 | |
| HK1252615A1 (zh) | Il-8-結合抗體及其應用 | |
| IL304772A (en) | Antibodies, uses and methods | |
| HK1250238A1 (zh) | 抗angptl8抗體及其用途 | |
| HK1243940A1 (zh) | 抗原肌肉生長抑制素/潛在肌肉生長抑制素的抗體及其用途 | |
| ZA201605894B (en) | Anti-egfrviii antibodies and uses thereof | |
| HK1256381A1 (zh) | 抗pacap抗體及其用途 | |
| GB201403875D0 (en) | Novel antibodies and uses thereof | |
| GB201413913D0 (en) | Novel antibodies and uses thereof | |
| IL247315B (en) | Anti-acth antibodies and their uses | |
| ZA201701663B (en) | Anti-il-25 antibodies and uses thereof | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof |